Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Mulampaka, Shiva Naresh ^a   Dixit, Narendra M ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; MARAVIROC; RAPAMYCIN; VICRIVIROC; 1 ((4,6 DIMETHYL 5 PYRIMIDINYL)CARBONYL) 4 (4 (2 METHOXY 4 (TRIFLUOROMETHYL)PHENYL)ETHYL 3 METHYL 1 PIPERAZINYL) 4 METHYLPIPERIDINE; 1-((4,6-DIMETHYL-5-PYRIMIDINYL)CARBONYL)-4-(4-(2-METHOXY-4-(TRIFLUOROMETHYL)PHENYL)ETHYL-3-METHYL-1-PIPERAZINYL)-4-METHYLPIPERIDINE; CYCLOHEXANE DERIVATIVE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALLOSTERISM; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUSION; CELL SURFACE; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PREDICTION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TARGET CELL; VIRUS ENTRY; VIRUS ENVELOPE; BIOLOGICAL MODEL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOLECULAR CLONING; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROTEIN BINDING; REPRODUCIBILITY;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

CLINICAL TRIALS, PHASE III AS TOPIC; CLONING, MOLECULAR; CYCLOHEXANES; DOWN-REGULATION; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN BINDING; PYRIMIDINES; RECEPTORS, CCR5; REPRODUCIBILITY OF RESULTS; SIROLIMUS; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 79957590948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019941     Document Type: Article

References (55)

1. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, et al. (2009) Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 15: 861-865.
2. Brenchley JM, Silvestri G, Douek DC, (2010) Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 32: 737-742.
3. Pandrea I, Apetrei C, (2010) Where the wild things are: Pathogenesis of SIV infection in African nonhuman primate hosts. Curr HIV/AIDS Rep 7: 28-36.
4. Pandrea I, Apetrei C, Gordon S, Barbercheck J, Dufour J, et al. (2007) Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 109: 1069-1076.
5. Lin Y-L, Mettling C, Portales P, Reynes J, Clot J, et al. (2002) Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 99: 15590-15595.
6. Heredia A, Amoroso A, Davis C, Le N, Reardon E, et al. (2003) Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 100: 10411-10416.
7. Pandrea I, Onanga R, Souquiere S, Mouinga-Ondeme A, Bourry O, et al. (2008) Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol 82: 5501-5509.
8. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
9. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
10. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, et al. (2010) Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 6: e1001052.
11. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
12. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, et al. (2003) The HIV Env-mediated fusion reaction. BBA Biomembranes 1614: 36-50.
13. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, et al. (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. The Journal of Cell Biology 151: 413-424.
14. Platt EJ, Durnin JP, Shinde U, Kabat D, (2007) An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations. J Mol Biol 374: 64-79.
15. Layne SP, Merges MJ, Dembo M, Spouge JL, Nara PL, (1990) HIV requires multiple gp120 molecules for CD4-mediated infection. Nature 346: 277-279.
16. Kuhmann SE, Platt EJ, Kozak SL, Kabat D, (2000) Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 74: 7005-7015.
17. Yang X, Kurteva S, Ren X, Lee S, Sodroski J, (2005) Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 79: 12132-12147.
18. Yang X, Kurteva S, Ren X, Lee S, Sodroski J, (2006) Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol 80: 4388-4395.
19. Klasse PJ, (2007) Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 369: 245-262.
20. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR, (2009) Estimating the stoichiometry of human immunodeficiency virus entry. J Virol 83: 1523-1531.
21. Magnus C, Regoes RR, (2010) Estimating the stoichiometry of HIV neutralization. PLoS Comput Biol 6: e1000713.
22. Lineberger JE, Danzeisen R, Hazuda DJ, Simon AJ, Miller MD, (2002) Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol 76: 3522-3533.
23. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
24. Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, et al. (2008) Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A 105: 20476-20481.
25. Markosyan RM, Leung MY, Cohen FS, (2009) The six-helix bundle of human immunodeficiency virus env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn. J Virol 83: 10048-10057.
26. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, et al. (2008) Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharm 73: 789-800.
27. Christopoulos A, (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1: 198-210.
28. Hu Q, Huang X, Shattock RJ, (2010) C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. J Gen Virol 91: 2965-2973.
29. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
30. Napier C, Sale H, Mosley M, Rickett G, Dorr P, et al. (2005) Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharm 71: 163-172.
31. Hladik F, Liu H, Speelmon E, Livingston-Rosanoff D, Wilson S, et al. (2005) Combined effect of CCR5-delta32 heterozygosity and the CCR5 promoter polymorphism-2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 79: 11677-11684.
32. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al. (2005) The Influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307: 1434-1440.
33. Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, et al. (2007) Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 364: 281-290.
34. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, et al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26: 257-270.
35. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB, (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444.
36. Miyauchi K, Kozlov MM, Melikyan GB, (2009) Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog 5: e1000585.
37. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, et al. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847-852.
38. Dobrowsky TM, Daniels BR, Siliciano RF, Sun SX, Wirtz D, (2010) Organization of cellular receptors into a nanoscale junction during HIV-1 adhesion. PLoS Comput Biol 6: e1000855.
39. Beaumier CM, Harris LD, Goldstein S, Klatt NR, Whitted S, et al. (2009) CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med 15: 879-885.
40. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
41. Popik W, Alce TM, Au W-C, (2002) Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J Virol 76: 4709-4722.
42. Percherancier Y, Lagane B, Planchenault T, Staropoli I, Altmeyer R, et al. (2003) HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J Biol Chem 278: 3153-3161.
43. Steffens CM, Hope TJ, (2003) Localization of CD4 and CCR5 in living cells. J Virol 77: 4985-4991.
44. Baker AM, Sauliere A, Gaibelet G, Lagane B, Mazeres S, et al. (2007) CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells: A fluorescence recovery after photobleaching at variable radii approach. J Biol Chem 282: 35163-35168.
45. Popik W, Alce TM, (2004) CD4 Receptor localized to non-raft membrane microdomains supports HIV-1 entry. J Biol Chem 279: 704-712.
46. Steffens CM, Hope TJ, (2004) Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: Implications for HIV fusion and entry events. J Virol 78: 9573-9578.
47. Viard M, Parolini I, Sargiacomo M, Fecchi K, Ramoni C, et al. (2002) Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol 76: 11584-11595.
48. Sougrat R, Bartesaghi A, Lifson JD, Bennett AE, Bess JW, et al. (2007) Electron tomography of the contact between T cells and SIV/HIV-1: Implications for viral entry. PLoS Pathog 3: e63.
49. Trister AD, Hammer DA, (2008) Trimerization on HIV binding elucidated with Brownian adhesive dynamics. Biophys J 95: 40-53.
50. Chang MI, Panorchan P, Dobrowsky TM, Tseng Y, Wirtz D, (2005) Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells. J Virol 79: 14748-14755.
51. Dobrowsky TM, Zhou Y, Sun SX, Siliciano RF, Wirtz D, (2008) Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution. J Virol 82: 7022-7033.
52. Zaitseva M, Peden K, Golding H, (2003) HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. BBA Biomembranes 1614: 51-61.
53. Doranz BJ, Baik SSW, Doms RW, (1999) Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 73: 10346-10358.
54. Bell GI, (1978) Models for the specific adhesion of cells to cells. Science 200: 618-627.
55. Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, et al. (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 49: 4911-4919.